Rev Med UAS
Vol. 13: No. 4. Octubre-Diciembre 2023
ISSN 2007-8013

Dermatofibrosarcoma Protuberans

Dermatofibrosarcoma Protuberans

Maradí Zumara Rubio-Rodríguez1, Víctor Fernando Muñoz-Estrada1, Rosal Anais Valenzuela-Marrufo2,*

  1. Médico adscrito, servicio de dermatología
  2. Médico residente de primer año de dermatología

Hospital Civil de Culiacán

*Autor de correspondencia: : Dra. Rosal Anaís Valenzuela-Marrufo
Departamento de Dermatología y Micología del Centro de Investigación y Docencia en Ciencias de la Salud,
Hospital Civil de Culiacán, UAS.
Eustaquio Buelna #91, Col. Gabriel Leyva. CP 80030.Culiacán, Sinaloa.
E-mail: rosal.mv93@gmail.com

DOI http://dx.doi.org/10.28960/revmeduas.2007-8013.v13.n4.012

Texto Completo PDF

Recibido 06 de agosto 2023, aceptado 22 de noviembre 2023

RESUMEN
El dermatofibrosarcoma protuberans (DFSP) es un sarcoma cutáneo derivado de los fibroblastos. Es más frecuente en hombres entre la tercera y cuarta decada de la vida. Este tumor se puede presentar como una placa o un nódulo color rosado que semeja una cicatriz. El diagnóstico se basa en la exploración física y se confirma con el estudio histopatológico e inmunohistoquímica. El tratamiento de elección es quirúrgico con margenes amplios libres de lesión; Sin embargo, se puede optar por radioterapia o inhibidor multicinasa como el imatinib. El pronóstico depende de la edad avanzada del paciente, la recurrencia de la enfermedad, su topografía y el tipo histológico
Palabras clave: Dermatofibrosarcoma protuberans, sarcoma, cirugía micrográfica de Mohs.

ABSTRACT
Dermatofibrosarcoma protuberans (DFSP) is a cutaneous sarcoma derived from fibroblasts. It is more frequent in men between the third and fourth decade of life. This tumor may present as a pink plaque or nodule that resembles a scar. The diagnosis is based on physical examination and is confirmed by histopathological and immunohistochemical study. The treatment of choice is surgery with wide lesion-free margins; However, radiotherapy or a multikinase inhibitor such as imatinib can be chosen. The prognosis depends on the advanced age of the patient, the recurrence of the disease, its topography and the histological type.
Keywords: Dermatofibrosarcoma protuberans, sarcoma, Mohs micrographic surgery

Referencias

  1. Larbcharoensub N, Kayankarnnavee J, Sanpaphant S, Kiranantawat K, Wirojtananugoon C, Sirikulchayanonta V. Clinicopathological features of dermatofibrosarcoma protuberans. Oncol Lett. 2016;11(1):661–7.
  2. Hao X, Billings SD, Wu F, Stultz TW, Procop GW, Mirkin G, et al. Dermatofibrosarcoma Protuberans : Update on the Diagnosis and Treatment. J Clin Med. 2020 Jun 5;9(6):1752
  3. Rouhani P, Fletcher CDM, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: An analysis of 12,114 cases. Cancer. 2008;113(3):616–27.
  4. Kreicher KL, Kurlander DE, Gittleman HR, Barnholtz-sloan JS, Bordeaux JS. Incidence and Survival of Primary Dermatofibrosarcoma Protuberans in the United States. Dermatol Surg. 2016 Jan;42 Suppl 1:S24-31
  5. Kuzel P, Metelitsa AI, Dover DC, Salopek TG. Epidemiology of dermatofibrosarcoma protuberans in Alberta, Canada, from 1988 to 2007. Dermatologic Surg. 2012;38(9):1461–8.
  6. Ibarra-Morales D, Moreno-López LM M-PP. Dermatofibrosarcoma protuberans: correlación clínico-patológica. Revisión de 43 años. Dermatol Rev Mex. 2022;66(3):331–40.
  7. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosom Cancer. 2003;37(1):1–19.
  8. Serra-Guillén C, Llombart B, Sanmartín O. Dermatofibrosarcoma protuberans. Actas Dermosifiliogr . 2012;103(9):762–77.
  9. Barrera J, Acosta A, Trujillo L. Dermatofibrosarcoma protuberans. Rev Colomb Cancerol. 2019;23(3):99–109.
  10. Torreggiani WC, Al-Ismail K, Munk PL, Nicolaou S, O'Connell JX, Knowling MA. Dermatofibrosarcoma protuberans: MR imaging features. AJR Am J Roentgenol. 2002 Apr;178(4):989-93
  11. Serra-Guillén C, Sanmartín O, Llombart B, Nagore E, Deltoro C, Martín I, et al. Correlation between preoperative magnetic resonance imaging and surgical margins with modified mohs for dermatofibrosarcoma protuberans. Dermatologic Surg. 2011;37(11):1638–45.
  12. Schmults CD. Dermatofibrosarcoma protuberans. NCCN Clin Pract Guidel Oncol. 2023;1.
  13. Ugurel S, Kortmann RD, Mohr P, Mentzel T, Garbe C, Breuninger H, et al. S1 guidelines for dermatofibrosarcoma protuberans (DFSP) – update 2018. JDDG - J Ger Soc Dermatol. 2019;663–8.
  14. Akram J, Wooler G, Lock-Andersen J. Dermatofibrosarcoma protuberans: Clinical series, national Danish incidence data and suggested guidelines. J Plast Surg Hand Surg. 2014;48(1):67–73.
  15. Wiesmueller F, Agaimy A, Perrakis A, Arkudas A, Horch RE, Grützmann R, Vassos N. Dermatofibrosarcoma protuberans: surgical management of a challenging mesenchymal tumor. World J Surg Oncol. 2019 May 28;17(1):90
  16. Huis EA, Grünhagen DJ, Van Coevorden F, Smith MJ, van Akkooi AC, Wouters MWJM, et al. Adequate surgical margins for dermatofibrosarcoma protuberans – A multi-centre analysis. Eur J Surg Oncol . 2021;47(2):436–42.
  17. Snow H, Davies E, Strauss DC, Smith M, Hayes AJ. Conservative Re-excision is a Safe and Simple Alternative to Radical Resection in Revision Surgery for Dermatofibrosarcoma Protuberans. Ann Surg Oncol 2020;27(3):919–23.
  18. Decanter G, Stoeckle E, Honore C, Meeus P, Mattei JC, Dubray-Longeras P, et al. Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate. Ann Surg Oncol. 2019;26(11):3526–34.
  19. Chen Y, Jiang G. Association between surgical excision margins and outcomes in patients with dermatofibrosarcoma protuberans: A meta-analysis. Dermatol Ther. 2021;34(4):1–8.
  20. Allen A, Ahn C, Sangüeza OP. Dermatofibrosarcoma Protuberans. Dermatol Clin . 2019;37(4):483–8.
  21. Nieto-Benito LM, Ciudad-Blanco C, Sanmartin-Jimenez O, Garces JR, Rodríguez-Prieto MA, Vilarrasa E, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans: Rate and risk factors for recurrence in a prospective cohort study from the Spanish Registry of Mohs Surgery (REGESMOHS) and review of the literature. Exp Dermatol. 2021;30(5):717–22.
  22. González Medina E, Lacy Niebla R, Boeta Ángeles L,Vega Memije M. Dermatofibrosarcoma protuberans: una revisión. Dermatol C . 2015;13(2):149–56.
  23. Bogucki B, Neuhaus I, Hurst EA. Dermatofibrosarcoma protuberans: A review of the literature. Dermatol Surg. 2012;38(4):537–51.
  24. Llombart B, Serra C, Requena C, Alsina M, Morgado-Carrasco D, Través V, et al. Guidelines for Diagnosis and Treatment of Cutaneous Sarcomas: Dermatofibrosarcoma Protuberans. Actas Dermosifiliogr. 2018;109(10):868–77.
  25. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A. © 199 7 Nature Publishing Group http://www.nature.com/naturegenetics. Nat Genet. 1997;15:57–61.
  26. Ugurel S, Becker JC. Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy? J Invest Dermatol. 2017;137(2):277–9.
  27. Castle KO, Guadagnolo BA, Tsai CJ, Feig BW, Zagars GK. Dermatofibrosarcoma protuberans: Long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys . 2013;86(3):585–90.
  28. Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer. 2004;101(11):2503–8.
  29. Chen YT, Tu WT, Lee WR, Huang YC. The efficacy of adjuvant radiotherapy in dermatofibrosarcoma protuberans: a systemic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30(7):1107–14.
  30. Kim BJ, Kim H, Jin US, Minn KW, Chang H. Wide Local Excision for Dermatofibrosarcoma Protuberans: A Single-Center Series of 90 Patients. Biomed Res Int. 2015;2015.